This post is from a suggested group
The Global Primary Osteoarthritis Market: Addressing the Burden of an Aging Population, Focusing on Symptomatic Relief, and Driving Research into Disease-Modifying Osteoarthritis Drugs (DMOADs)
The Primary Osteoarthritis (OA) Market is characterized by immense size and steady growth, fundamentally driven by the inexorable aging of the global population and the increasing prevalence of risk factors, including obesity and joint injury, which accelerate the progression of this most common form of degenerative joint disease. The primary market catalyst is the high unmet clinical need for effective pain relief and functional restoration for millions of patients, most commonly affecting the knee, hip, and hand joints, which severely impacts daily living and quality of life. The discussion must emphasize that the market is currently dominated by symptomatic treatments, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, and hyaluronic acid viscosupplementation, which aim to manage pain and inflammation but do not halt the underlying structural damage.…